不同雾化吸入药物治疗老年慢性支气管炎的临床疗效分析

龙源期刊网 https://www.360docs.net/doc/b310939394.html,

不同雾化吸入药物治疗老年慢性支气管炎的临床疗效分析

作者:徐文华

来源:《中国实用医药》2016年第19期

【摘要】目的探究不同雾化吸入药物治疗老年慢性支气管炎的临床疗效。方法 40例典型慢性支气管炎患者,采用随机数字表法分成试验组和对照组,各20例。试验组采用盐酸氨溴索(沐舒坦)联合布地奈德吸入的治疗方案,对照组采用布地奈德单独吸入的治疗方案。观察两组患者症状缓解时间及总有效率等情况。结果试验组咳嗽缓解时间为(5.2±1.1)d、喘息缓解时间为(4.9±1.3)d,短于对照组的[(8.2±1.9)、(7.2±2.1)d](P

【关键词】盐酸氨溴索;布地奈德;雾化吸入;慢性支气管炎

DOI:10.14163/https://www.360docs.net/doc/b310939394.html,ki.11-5547/r.2016.19.020

Analysis of clinical effects by different aerosol inhalation drugs in the treatment of senile chronic bronchitis XU Wen-hua. Department of Internal Medicine, Shanghai Dongfang Medical Group Suqian Dongfang Hospital, Suqian 223800, China

【Abstract】 Objective To investigate clinical effects by different aerosol inhalation drugs in the treatment of senile chronic bronchitis. Methods A total of 40 patients with typical chronic bronchitis were divided by random number table into experimental group and control group, with 20 cases in each group. The experimental group received ambroxol hydrochloride (mucosolvan) combined with budesonide inhalation, and the control group received single budesonide inhalation. Symptom relief time and total effective rate were observed in both groups. Results The experimental group had obviously shorter cough relief time as (5.2±1.1) d and gasp relief time as (4.9±1.3) d than (8.2±1.9) and (7.2±2.1) d of the control group (P

【Key words】 Ambroxol hydrochloride; Budesonide; Aerosol inhalation; Chronic bronchitis

慢性支气管炎是呼吸内科常见病,是一种气管及支气管部位的慢性非特异性炎症,其发病因素较为复杂,与病毒感染、细菌感染等外部因素、过敏因素等外因及自身呼吸防御功能

异常、自主神经功能异常等内因有关[1]。慢性支气管炎可以对人体造成直接伤害,若病情没有得到良好的控制,长期发展下去会导致慢性阻塞性肺疾病、肺气肿等严重呼吸系统疾病,

严重影响患者生存质量,甚至威胁患者生命[2]。雾化吸入疗法是目前治疗此病比较常用的方法,本院采用沐舒坦联合布地奈德雾化吸入的方法治疗此病,控制呼吸困难及咳嗽的症状,现报告如下。

相关文档
最新文档